Preclinical translational screening of palladium(II)-porphyrin photosensitizers across human and Oncopig bladder cancer cell lines - Report - MDSpire

Preclinical translational screening of palladium(II)-porphyrin photosensitizers across human and Oncopig bladder cancer cell lines

  • By

  • Valentina G. Ferreira

  • Maria Eduarda Ehlert

  • Bruna S. Pacheco

  • Fernanda S. S. Souza

  • Isadora Tisoco

  • Lucas Damé Simões

  • Bernardo A. Iglesias

  • Claudia Ó. Pessoa

  • Fabiana K. Seixas

  • Maria Lucia Z. Dagli

  • Laurie A. Rund

  • Kyle M. Schachtschneider

  • Lawrence B. Schook

  • Tiago Veiras Collares

  • July 9, 2026

  • 0 min

Share

Clinical Report: In Vitro Evaluation of Palladium(II)-Porphyrin Photosensitizers

Overview

This study evaluates the cytotoxic effects of three palladium(II)-porphyrins in human and Oncopig bladder cancer cell lines. The findings indicate that these compounds exhibit light-dependent cytotoxicity.

Background

Bladder cancer is a prevalent malignancy with high recurrence rates and limited long-term treatment success. The development of new therapies is challenged by the lack of preclinical models that accurately mimic human disease.

Data Highlights

CompoundIC50 (nM)Photodynamic Activity
3-Pd(PPh3)LowHigh
3-Pd(dppf)LowHigh
3-Pd(PEPSI)HighLow

Key Findings

  • All three palladium(II)-porphyrins showed light-dependent cytotoxicity with minimal dark toxicity.
  • 3-Pd(PPh3) and 3-Pd(dppf) demonstrated potent photodynamic activity with nanomolar IC50 values.
  • 3-Pd(PEPSI) exhibited higher IC50 values, indicating lower photodynamic potency.
  • Photoactivation resulted in significant ROS production and upregulation of apoptosis markers.
  • Oncopig-derived cells exhibited responses closely matching human bladder cancer cell lines.

Clinical Implications

The study presents findings on palladium(II)-porphyrins as photosensitizers for bladder cancer photodynamic therapy.

Conclusion

The findings support the use of Pd(II)-porphyrins for bladder cancer treatment.

Related Resources & Content

  1. EAU Guidelines on Non-muscle-invasive Bladder Cancer - Uroweb, 2026 -- Summary of changes
  2. The Oncopig bladder cancer model, an innovative large animal platform for evaluating treatment effects. | Journal of Clinical Oncology, 2025 -- Study on Oncopig model
  3. Archives of Toxicology — Polycyclic Aromatic Hydrocarbons with Carcinogenic Potential Activate CYP1A1 in Human Cells through a p53-Dependent Pathway
  4. Archives of Toxicology — Utilization of HuH6 and other human hepatoma cell lines for genotoxin detection: a promising alternative to animal testing?
  5. Archives of Toxicology — Co-exposure to Benzo[a]pyrene and UV Radiation: Varied Impacts on Oxidative Stress and Genotoxic Effects in Human Keratinocytes and Ex Vivo Skin
  6. Efficacy Assessment of Intravesical Immunomodulators TMX-101 and TMX-202 in a Placebo-Controlled Study Using a Rat Model of Orthotopic Bladder Cancer
  7. EAU Guidelines on Non-muscle-invasive Bladder Cancer - Uroweb
  8. Diagnostic performance of narrow-band imaging and photodynamic diagnosis compared to white light cystoscopy for non-muscle invasive bladder cancer: A network meta-analysis of randomized trials - PMC
  9. The Oncopig bladder cancer model, an innovative large animal platform for evaluating treatment effects. | Journal of Clinical Oncology

Original Source(s)

Preclinical translational screening of palladium(II)-porphyrin photosensitizers across human and Oncopig bladder cancer cell lines

  • by Valentina G. Ferreira, Maria Eduarda Ehlert, Bruna S. Pacheco, Fernanda S. S. Souza, Isadora Tisoco, Lucas Damé Simões, Bernardo A. Iglesias, Claudia Ó. Pessoa, Fabiana K. Seixas, Maria Lucia Z. Dagli, Laurie A. Rund, Kyle M. Schachtschneider, Lawrence B. Schook, Tiago Veiras Collares

  • July 9, 2026

Related Content

Identification and validation of prognostic genes associated with clear cell renal cell carcinoma: based on public whole transcriptome sequencing datasets

Intratumoral and peritumoral MRI habitat imaging for differentiating stage IA endometrial cancer from benign endometrial lesions: a multicenter study

Clinical features and treatment challenges of HER2-positive primary breast squamous cell carcinoma: a case report and literature review